ModifiedCentenePolicy CP MP.69

Intensity-Modulated Radiotherapy (IMRT)

Medical necessity criteria and coding implications for intensity-modulated radiotherapy (IMRT) for non-Medicare Centene-affiliated health plans; describes clinical indications, background, and referenced codes and guidance.

Policy Summary

PayerCentene

PolicyIntensity-Modulated Radiotherapy (IMRT)

Policy CodePolicy CP MP.69

Change TypeMaterial criteria additions and breast criteria simplification

Effective Date

Next Review Date

Key ActionRequest prior authorization for IMRT services using the listed CPT (77301, 77338, 77385, 77386) or HCPCS (G6015, G6016) codes and cite the medical necessity criteria with supporting documentation.

SourceLink

POLICY UPDATE CHANGES

Added Criteria I.G.9. uterine neoplasms and I.G.10. pancreatic cancer and I.G.11. stage III non-small cell lung cancer.

Removed I.G.8.a.i-iii regarding maximum dose volume, volume of breast tissue and hot spots in inframammary fold.

Changed certain breast criteria to focus on homogeneity of dose and specific situations (e.g., left-sided cancers when treating internal mammary nodes, use with external beam APBI).

Added note to refer to MC.CP.MP.69 for Medicare criteria and specified 'non-Medicare' for health plans in Policy/Criteria L.

~40+distinct cancer site indications listed or referenced

4IMRT-related CPT/HCPCS codes explicitly listed

2HCPCS G-codes listed

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Medical Necessity and Coverage Criteria

Covered Indications (Initial and Site-specific)

IMRT is medically necessary for non‑Medicare Centene‑affiliated health plans when ANY of the following indications apply:

IMRT medical necessity indications: A. Age < 18 years with a solid tumor; B. Medically inoperable patient with diagnosis of cancer where dose escalation is required; C. Re-irradiation where cumulative critical structure dose would exceed tolerance; D. Primary malignant or benign bone tumors; E. Site-specific indications as listed (see children).

Site-specific list follows

Site-specific indications

Central Nervous System: Tumors that approach or are located at the base of skull; primary CNS tumors; primary spine or metastatic tumors to the spine or spinal cord where organ-at-risk tolerance may be exceeded with 3D conformal treatments; tumors requiring craniospinal irradiation; brain metastases requiring hippocampal-sparing whole brain radiotherapy.
Head and Neck: Definitive, adjuvant, or palliative treatment of primary/secondary head and neck cancers or draining lymphatics (including but not limited to nasopharynx, nasal cavity, paranasal sinuses, oropharynx, oral cavity, hypopharynx, larynx, thyroid, salivary glands); cutaneous tumors with cranial nerve invasion to base of skull, cavernous sinus, and/or brainstem; mucosal melanoma; occult primary head and neck malignancies.
Breast: Bilateral breast cancers requiring nodal treatment on at least one side; patients treated with definitive intent who have unfavorable anatomy (e.g., pectus excavatum) that would deliver unacceptably high doses to organs at risk; accelerated partial breast irradiation (APBI); early-stage disease when heart dose is unacceptably high with conventional techniques; targeting internal mammary nodes; post-mastectomy radiotherapy with bilateral implant reconstruction; limited ipsilateral arm range of motion requiring arms‑down positioning; whole breast radiotherapy in patients with bilateral augmentation implants.
Thoracic: Early-stage lung cancer for which SBRT is not feasible due to anatomic considerations; primary or secondary tumors of the mediastinum including thymic tumors, mediastinal lymphomas and thoracic sarcomas; locally advanced disease in which IMRT significantly reduces dose to normal tissues (examples: bilateral mediastinal disease, paraspinal tumors, N3 disease, or to reduce esophageal dose).
Gastrointestinal: Primary cancers of the esophagus and gastroesophageal junction; hepatocellular carcinoma; bile duct, gallbladder and cholangiocarcinoma; malignant pleural mesothelioma; primary and secondary liver cancers; abdominal malignancies including pancreatic, gastric and adrenal cancers; anal and colorectal cancers.
Sarcomas: Retroperitoneal sarcomas; desmoid tumors; soft tissue sarcomas where organ-at-risk constraints cannot be met with non-IMRT techniques.
Gynecologic: Endometrial, cervical, vulvar, and vaginal cancers.
Genitourinary: Prostate, renal, bladder, penile, and ureteral cancers.

This policy was revised during the 04/24 annual review to simplify the breast-related criteria. Specifically, prior subcriteria I.G.8.a.i–iii regarding maximum dose volume, volume of breast tissue, and hot spots in the inframammary fold were removed. The breast indication language was refocused to emphasize dose homogeneity and specific clinical situations (for example, left-sided cancers when treating internal mammary nodes and use with external beam accelerated partial breast irradiation).

Coverage under this clinical policy is a guide to medical necessity and does not itself constitute a contract or guarantee of payment. Coverage decisions and the administration of benefits remain subject to all terms, conditions, exclusions, and limitations set forth in the applicable coverage documents (for example, evidence of coverage, certificate of coverage, policy, or contract of insurance).

Services billed using IMRT procedure codes (e.g., CPT 77301, 77338, 77385, 77386 and HCPCS G6015/G6016) must correspond to an indication listed in this policy and be supported by clinical documentation. Documentation should include the diagnosis, site-specific indication, prior treatments when relevant (such as for re-irradiation), and justification that IMRT is required to meet organ-at-risk constraints or dose-escalation needs. Failure to document the medical necessity consistent with the policy may result in denial.

Billing Codes and Status

Covered CPT CodesCPTCovered

77301	Intensity modulated radiotherapy plan, including dose-volume histograms for target and critical structure_partial tolerance specifications_
77338	Multi-leaf collimator (MLC) device(s) for intensity modulated radiation therapy (IMRT) design and construction per IMRT_plan_
77385	Intensity modulated radiation treatment delivery (IMRT), includes guidance and tracking__when performed; simple_
77386	Intensity modulated radiation treatment delivery (IMRT), includes guidance and tracking,_when performed;_complex

HCPCS/G-codesHCPCSCovered

G6015	Intensity modulated treatment delivery, single Or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session.
G6016	Compensator-based beam modulation treatment delivery of inverse planned treatment using three or more high resolution (milled or cast) compensator; convergent beam modulated fields,per treatment session

Provider Requirements, Prior Authorization, and Denial Risks

Prior Authorization

Prior Authorization Required

Prior authorization is required for IMRT-coded services. Providers must obtain prior authorization as required by the Health Plan before delivering IMRT services coded with CPT 77301, 77338, 77385, 77386 or HCPCS G6015, G6016.

Prior authorization required when billing CPT 77301, 77338, 77385, 77386, and HCPCS G6015, G6016.
Submit clinical documentation to support medical necessity at time of prior authorization request.

Note

Prior Authorization and Effective Date Advisory

The effective date for this clinical policy is determined by the Health Plan. The posting date may not be the effective date; providers must follow the Health Plan-level prior authorization rules and any applicable legal/regulatory requirements that supersede the policy posting.

Coverage and prior authorization requirements are governed by the Health Plan effective date and administrative policies.
If state Medicaid provisions conflict with this policy, state Medicaid provisions take precedence.

Clinical Background and Rationale

Intensity-modulated radiotherapy (IMRT) delivers highly conformal external beam radiation by varying beam intensity across treatment fields, allowing escalation of dose to targets adjacent to sensitive normal tissues while sparing organs at risk. IMRT planning is a multi-step process that includes detailed contouring to define targets and avoid normal structures. While IMRT improves conformality and dose modulation, planning and quality assurance are essential to manage potential concerns such as dose inhomogeneity and increased low-dose exposure to larger normal volumes. IMRT (and VMAT) is widely used and recommended for indications where critical structures are at risk.

Key Definitions

IMRT — definition and characteristics

TermIntensity-modulated radiotherapy (IMRT)

DefinitionA form of external-beam radiation therapy that delivers highly conformal doses to specified targets by varying the intensity within radiation beams across treatment fields.

Key characteristicsUses multi-step planning with contouring to define targets and spare normal structures; allows simultaneous treatment of multiple areas within a target to different dose levels.

Clinical advantagesEnables dose escalation to targets near sensitive organs at risk while reducing dose to those structures, improving dose homogeneity in some settings (e.g., breast cancer).

Practical considerationsRequires additional planning computation and quality assurance (QA) and may increase low-dose exposure to larger volumes of normal tissue.